Stock Market Explodes After Biden Administration Urges Reclassifying Cannabis September 5, 2023 Steven Schain Descheduling or Rescheduling Marijuana 0 Comments By Steve Schain Causing a day-long, double-digit Cannabis stock surge peaking at 40.56%, on August 30, 2023, the U.S. Department of Health and Human Services (“HHS”) recommended that the U.S. Drug Enforcement Administration (“DEA”) reschedule Marijuana from Schedule I to… Read More→
Synthetic vs. Natural Hemp: A Legal and Labeling Minefield November 11, 2020 Henry Baskerville Compliance and Regulations, Hemp Policy & Legal, Lab Testing, Policy & Legal, Processing, Standards and Certification 0 Comments The DEA’s recent interim final rule--which appears to be in contravention of the letter and spirit of the Agricultural Improvement Act of 2018 (aka the Farm Bill)--continues to cause concern and turmoil in the industry. The proposed rule addresses CBD… Read More→
Tilray® Receives Approval from U.S. Government to Import a Medical Cannabis Study Drug for a Clinical Trial at the University of California San Diego Center for Medicinal Cannabis Research September 18, 2018 Press Release Policy & Legal, Press Releases 0 Comments PRESS RELEASE U.S. Drug Enforcement Administration approves import of a pharmaceutical-grade medical cannabis product produced by Tilray into the United States for a clinical trial focused on Essential Tremor NANAIMO, B.C. – Tilray Inc. (NASDAQ:TLRY) today announced that the U.S.… Read More→